Sex differences in neural regulation of hypertension

Hypertension and the Brain as an End-Organ Target

Volumn , Issue , 2016, Pages 195-221

  Van Kempen, Tracey A ^a   Marques Lopes, Jose ^a   Glass, Michael J ^a   Milner, Teresa A ^a,b  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Angiotensin; Estrogen receptors; Reactive oxygen species

Indexed keywords

EID: 84960311416     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-25616-0_10     Document Type: Chapter

References (151)

1. Dunn KM, Nelson MT. Neurovascular signaling in the brain and the pathological consequences of hypertension. Am J Physiol Heart Circ Physiol. 2014;306: H1-14. doi: 10.1152/ajpheart.00364.2013.
2. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62: 810-7. doi: 10.1161/HYPERTENSIONAHA.113.01063.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PWF, Woo YJ, American Heart Association Advocacy Coordinating Committee, Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary, Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123: 933-44. doi: 10.1161/CIR.0b013e31820a55f5.
4. Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ. 2012;3: 7. doi: 10.1186/2042-6410-3-7.
5. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study (2012) Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. 60, 1393-1399. doi: 10.1161/HYPERTENSIONAHA.112.201780
6. Martins D, Nelson K, Pan D, Tareen N, Norris K. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J Gend Specif Med. 2001;4(3): 103.
7. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US populatio. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26: 60-9.
8. Roger VL, O’Donnell CJ. Population health, outcomes research, and prevention: example of the American Heart Association 2020 goals. Circ Cardiovasc Qual Outcomes. 2012;5: 6-8. doi: 10.1161/CIRCOUTCOMES.111.964734.
9. Sadeghi M, Khalili M, Pourmoghaddas M, Talaei M. The correlation between blood pressure and hot flashes in menopausal women. ARYA Atheroscler. 2012;8: 32-5.
10. Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control during women’s daily lives. Menopause. 2012;19: 406-12. doi: 10.1097/gme.0b013e3182337166.
11. Hay M, Xue B, Johnson AK. Yes! sex matters: sex, the brain and blood pressure. Curr Hypertens Rep. 2014;16(8): 458. doi: 10.1007/s11906-014-0458-4.
12. Saranya K, Pal GK, Habeebullah S, Pal P. Assessment of cardiovascular autonomic function in patients with polycystic ovary syndrome. J Obstet Gynaecol Res. 2014;40: 192-9. doi: 10.1111/jog.12154.
13. Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach J, Joyner MJ. Sex and ageing differences in resting arterial pressure regulation: the role of the β-adrenergic receptors. J Physiol (Lond). 2011;589: 5285-97. doi: 10.1113/jphysiol.2011.212753.
14. Freedman RR, Kruger ML, Wasson SL. Heart rate variability in menopausal hot flashes during sleep. Menopause. 2011;18: 897-900. doi: 10.1097/gme.0b013e31820ac941.
15. de Zambotti M, Colrain IM, Sassoon SA, Nicholas CL, Trinder J, Baker FC. Vagal withdrawal during hot flashes occurring in undisturbed sleep. Menopause. 2013;20: 1147-53. doi: 10.1097/GME.0b013e31828aa344.
16. Lantto H, Haapalahti P, Tuomikoski P, Viitasalo M, Väänänen H, Sovijärvi ARA, Ylikorkala O, Mikkola TS. Vasomotor hot flashes and heart rate variability. Menopause. 2012;19: 82-8. doi: 10.1097/gme.0b013e318221bae8.
17. Corbelli J, Shaikh N, Wessel C, Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2014;22: 897-900. doi: 10.1097/GME.0000000000000258.
18. Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13: 411-22. doi: 10.1097/01.gme.0000189618.48774.7b.
19. Tuomikoski P, Haapalahti P, Sarna S, Ylikorkala O, Mikkola TS. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: a placebo-controlled trial on post-menopausal hormone therapy. Ann Med. 2010;42: 334-43. doi: 10.3109/07853891003796760.
20. Ji H, Zheng W, Wu X, Liu J, Ecelbarger CM, Watkins R, Arnold AP, Sandberg K. Sex chromosome effects unmasked in angiotensin II-induced hypertension. Hypertension. 2010;55: 1275-82. doi: 10.1161/HYPERTENSIONAHA.109.144949.
21. Jessup JA, Wang H, MacNamara LM, Presley TD, Kim-Shapiro DB, Zhang L, Chen AF, Groban L. Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats. Menopause. 2013;20: 860-8. doi: 10.1097/GME.0b013e318280589a.
22. Mayer LP, Dyer CA, Eastgard RL, Hoyer PB, Banka CL. Atherosclerotic lesion development in a novel ovary-intact mouse model of perimenopause. Arterioscler Thromb Vasc Biol. 2005;25: 1910-6. doi: 10.1161/01.ATV.0000175767.46520.6a.
23. Saleh MC, Connell BJ, Saleh TM. Medullary and intrathecal injections of 17beta-estradiol in male rats. Brain Res. 2000;867: 200-9.
24. Saleh MC, Connell BJ, Saleh TM. Autonomic and cardiovascular reflex responses to central estrogen injection in ovariectomized female rats. Brain Res. 2000;879: 105-14.
25. Saleh TM, Connell BJ, Saleh MC. Acute injection of 17beta-estradiol enhances cardiovascular reflexes and autonomic tone in ovariectomized female rats. Auton Neurosci. 2000;84: 78-88.
26. Xue B, Singh M, Guo F, Hay M, Johnson AK. Protective actions of estrogen on angiotensin II-induced hypertension: role of central nitric oxide. Am J Physiol Heart Circ Physiol. 2009;297: H1638-46. doi: 10.1152/ajpheart.00502.2009.
27. Wang G, Milner TA, Speth RC, Gore AC, Wu D, Iadecola C, Pierce JP. Sex differences in angiotensin signaling in bulbospinal neurons in the rat rostral ventrolateral medulla. Am J Physiol Regul Integr Comp Physiol. 2008;295: R1149-57. doi: 10.1152/ajpregu.90485.2008.
28. Cao X, Peterson JR, Wang G, Anrather J, Young CN, Guruju MR, Burmeister MA, Iadecola C, Davisson RL. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain. Hypertension. 2012;59: 869-76. doi: 10.1161/HYPERTENSIONAHA.111.182071.
29. Marques Lopes J, Van Kempen TA, Waters EM, Pickel VM, Iadecola C, Milner TA. Slowpressor angiotensin II hypertension and concomitant dendritic NMDA receptor trafficking in estrogen receptor beta-containing neurons of the mouse hypothalamic paraventricular nucleus are sex and age dependent. J Comp Neurol. 2014. doi: 10.1002/cne.23569.
30. Duckles SP, Krause DN. Cerebrovascular effects of oestrogen: multiplicity of action. Clin Exp Pharmacol Physiol. 2007;34: 801-8. doi: 10.1111/j.1440-1681.2007.04683.x.
31. Xue B, Johnson AK, Hay M. Sex differences in angiotensin II-and aldosterone-induced hypertension: the central protective effects of estrogen. Am J Physiol Regul Integr Comp Physiol. 2013;305: R459-63. doi: 10.1152/ajpregu.00222.2013.
32. Xue B, Zhang Z, Beltz TG, Guo F, Hay M, Johnson AK. Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension. Am J Physiol Heart Circ Physiol. 2014;307: H191-8. doi: 10.1152/ajpheart.01012.2013.
33. Rosas-Arellano PM, Solano-Flores PL, Ciriello J. Co-localization of estrogen and angiotensin receptors within subfornical organ neurons. Brain Res. 1999;837: 254-62. doi: 10.1016/S0006-8993(99)01672-8.
34. Spary EJ, Maqbool A, Batten TFC. Oestrogen receptors in the central nervous system and evidence for their role in the control of cardiovascular function. J Chem Neuroanat. 2009;38: 185-96. doi: 10.1016/j.jchemneu.2009.05.008.
35. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res. 2002;57: 357-84.
36. Roepke TA, Qiu J, Bosch MA, Rønnekleiv OK, Kelly MJ. Cross-talk between membraneinitiated and nuclear-initiated oestrogen signalling in the hypothalamus. J Neuroendocrinol. 2009;21: 263-70. doi: 10.1111/j.1365-2826.2009.01846.x.
37. Roepke TA, Rønnekleiv OK, Kelly MJ. Physiological consequences of membrane-initiated estrogen signaling in the brain. Front Biosci (Landmark Ed). 2011;16: 1560-73.
38. McEwen BS, Akama KT, Spencer-Segal JL, Milner TA, Waters EM. Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci. 2012;126: 4-16. doi: 10.1037/a0026708.
39. Arias-Loza PA, Jazbutyte V, Pelzer T. Genetic and pharmacologic strategies to determine the function of estrogen receptor α and estrogen receptor β in cardiovascular system. Gend Med. 2008;5: S34-45. doi: 10.1016/j.genm.2008.03.005.
40. Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol. 2007;292: H1770-6. doi: 10.1152/ajpheart.01011.2005.
41. Pedram A, Razandi M, Korach KS, Narayanan R, Dalton JT, Levin ER. ERβ Selective Agonist Inhibits Angiotensin-Induced Cardiovascular Pathology in Female Mice. Endocrinology. 2013;154: 4352-64. doi: 10.1210/en.2013-1358.
42. Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, Dun NJ. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol. 2007;193: 311-21. doi: 10.1677/JOE-07-0017.
43. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011. doi: 10.1161/HYPERTENSIONAHA.110.161653.
44. Sakamoto H, Matsuda K-I, Hosokawa K, Nishi M, Morris JF, Prossnitz ER, Kawata M. Expression of G protein-coupled receptor-30, a G protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology. 2007;148: 5842-50. doi: 10.1210/en.2007-0436.
45. Akama KT, Thompson LI, Milner TA, McEwen BS. Post-synaptic density-95 (PSD-95) binding capacity of G-protein-coupled receptor 30 (GPR30), an estrogen receptor that can be identified in hippocampal dendritic spines. J Biol Chem. 2013;288: 6438-50. doi: 10.1074/jbc.M112.412478.
46. Nilsson B-O, Olde B, Leeb-Lundberg LMF. G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling. Br J Pharmacol. 2011;163: 1131-9. doi: 10.1111/j.1476-5381.2011.01235.x.
47. Mani SK, Mermelstein PG, Tetel MJ, Anesetti G. Convergence of multiple mechanisms of steroid hormone action. Horm Metab Res. 2012;44: 569-76. doi: 10.1055/s-0032-1306343.
48. Haywood SA, Simonian SX, van der Beek EM, Bicknell RJ, Herbison AE. Fluctuating estrogen and progesterone receptor expression in brainstem norepinephrine neurons through the rat estrous cycle. Endocrinology. 1999;140: 3255-63. doi: 10.1210/endo.140.7.6869.
49. Milner TA, Drake CT, Lessard A, Waters EM, Torres-Reveron A, Graustein B, Mitterling K, Frys K, Iadecola C. Angiotensin II-induced hypertension differentially affects estrogen and progestin receptors in central autonomic regulatory areas of female rats. Exp Neurol. 2008;212: 393-406. doi: 10.1016/j.expneurol.2008.04.021.
50. Simonian SX, Herbison AE. Localization of neuronal nitric oxide synthase-immunoreactivity within sub-populations of noradrenergic A(1) and A(2) neurons in the rats. Brain Res. 1996;732: 247-52. doi: 10.1016/0006-8993(96)00687-7.
51. Doncarlos LL, Garcia-Ovejero D, Sarkey S, Garcia-Segura LM, Azcoitia I. Androgen receptor immunoreactivity in forebrain axons and dendrites in the rat. Endocrinology. 2003;144: 3632-8. doi: 10.1210/en.2002-0105.
52. Hamson DK, Jones BA, Watson NV. Distribution of androgen receptor immunoreactivity in the brainstem of male rats. Neuroscience. 2004;127: 797-803. doi: 10.1016/j.neuroscience.2004.06.006.
53. Xue B. Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol. 2005;288: H2177-84. doi: 10.1152/ajpheart.00969.2004.
54. Fortepiani LA, Yanes L, Zhang H, Racusen LC, Reckelhoff JF. Role of androgens in mediating renal injury in aging SHR. Hypertension. 2003;42: 952-5. doi: 10.1161/01. HYP.0000099241.53121.7F.
55. Milner TA, Ayoola K, Drake CT, Herrick SP, Tabori NE, McEwen BS, Warrier S, Alves SE. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J Comp Neurol. 2005;491: 81-95. doi: 10.1002/cne.20724.
56. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90: 3847-53. doi: 10.1210/jc.2005-0212.
57. Leenen FHH. Actions of Circulating Angiotensin II and Aldosterone in the Brain Contributing to Hypertension. Am J Hypertens. 2014;27: 1024-32. doi: 10.1093/ajh/hpu066.
58. De Luca LA, Menani JV, Johnson AK, Vieira AA, Colombari DSA, De Paula PM, Colombari E, De Luca LA. Preoptic-periventricular integrative mechanisms involved in behavior, fluid-electrolyte balance, and pressor responses. Boca Raton: CRC; 2014.
59. Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, Sigmund CD. Local production of angiotensin II in the subfornical organ causes elevated drinking. J Clin Invest. 2007;117: 1088-95. doi: 10.1172/JCI31242.
60. Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology. 2008;23: 187-93. doi: 10.1152/physiol.00002.2008.
61. Grobe JL, Xu D, Sigmund CD. The brain renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Physiology. 2010;12: 431-42. doi: 10.1016/j.cmet.2010.09.011.
62. Macova M, Pavel J, Saavedra JM. A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res. 2009;1250: 130-40. doi: 10.1016/j.brainres.2008.11.006.
63. Gonzalez AD, Wang G, Waters EM, Gonzales KL, Speth RC, Van Kempen TA, Marques Lopes J, Young CN, Butler SD, Davisson RL, Iadecola C, Pickel VM, Pierce JP, Milner TA. Distribution of angiotensin type 1a receptor-containing cells in the brains of bacterial artificial chromosome transgenic mice. Neuroscience. 2012;226: 489-509. doi: 10.1016/j. neuroscience.2012.08.039.
64. Chan SHH, Chan JYH. Brain stem NOS and ROS in neural mechanisms of hypertension. Antioxid Redox Signal. 2014;20: 146-63. doi: 10.1089/ars.2013.5230.
65. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87: 245-313. doi: 10.1152/physrev.00044.2005.
66. Nauseef WM. Biological roles for the NOX family NADPH oxidases. J Biol Chem. 2008;283: 16961-5. doi: 10.1074/jbc.R700045200.
67. Jones SA, Wood JD, Coffey MJ, Jones O. The functional expression of P47-Phox and P67-Phox may contribute to the generation of superoxide by an NADPH oxidase-like system in human fibroblasts. FEBS Lett. 1994;355: 178-82.
68. Wang G, Coleman CG, Chan J, Faraco G, Marques Lopes J, Milner TA, Guruju MR, Anrather J, Davisson RL, Iadecola C, Pickel VM. Angiotensin II slow-pressor hypertension enhances NMDA currents and NOX2-dependent superoxide production in hypothalamic paraventricular neurons. Am J Physiol Regul Integr Comp Physiol. 2013;304: R1096-106. doi: 10.1152/ajpregu.00367.2012.
69. Wang G, Wang G, Anrather J, Huang J, Speth RC, Pickel VM, Iadecola C. NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius. J Neurosci. 2004;24: 5516-24. doi: 10.1523/JNEUROSCI.1176-04.2004.
70. Girouard H, Wang G, Gallo EF, Anrather J, Zhou P, Pickel VM, Iadecola C. NMDA receptor activation increases free radical production through nitric oxide and NOX2. J Neurosci. 2009;29: 2545-52. doi: 10.1523/JNEUROSCI.0133-09.2009.
71. Kimura Y, Hirooka Y, Kishi T, Sagara Y, Sunagawa K. Role of inducible nitric oxide synthase in rostral ventrolateral medulla in blood pressure regulation in spontaneously hypertensive rats. Clin Exp Hypertens. 2009;31: 281-6. doi: 10.1080/10641960902822534.
72. Zimmerman MC, Sharma RV, Davisson RL. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. Hypertension. 2005;45: 717-23. doi: 10.1161/01. HYP.0000153463.22621.5e.
73. Wang G, Sarkar P, Peterson JR, Anrather J, Pierce JP, Moore JM, Feng J, Zhou P, Milner TA, Pickel VM, Iadecola C, Davisson RL. COX-1-derived PGE2 and PGE2 type 1 receptors are vital for angiotensin II-induced formation of reactive oxygen species and Ca(2+) influx in the subfornical organ. Am J Physiol Heart Circ Physiol. 2013;305: H1451-61. doi: 10.1152/ajpheart.00238.2013.
74. Coleman CG, Wang G, Faraco G, Marques Lopes J, Waters EM, Milner TA, Iadecola C, Pickel VM. Membrane trafficking of NADPH oxidase p47phox in paraventricular hypothalamic neurons parallels local free radical production in angiotensin II slow-pressor hypertension. J Neurosci. 2013;33: 4308-16. doi: 10.1523/JNEUROSCI.3061-12.2013.
75. Malenka RC, Nicoll RA. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 1993;16: 521-7.
76. Wenthold RJ, Prybylowski K, Standley S, Sans N, Petralia RS. Trafficking of NMDA receptors 1. Annu Rev Pharmacol Toxicol. 2003;43: 335-58. doi: 10.1146/annurev.pharmtox.43.100901.135803.
77. Wehrwein EA, Joyner MJ. Regulation of blood pressure by the arterial baroreflex and autonomic nervous system. Handb Clin Neurol. 2014;117: 89-102.
78. Machado BH. Neurotransmission of the cardiovascular reflexes in the nucleus tractus solitarii of awake rats. Ann N Y Acad Sci. 2001;940: 179-96.
79. Aicher SA, Milner TA, Pickel VM, Reis DJ. Anatomical substrates for baroreflex sympathoinhibition in the rat. Brain Res Bull. 2000;51: 107-10.
80. Guyenet PG, Stornetta RL, Bochorishvili G, DePuy SD, Burke PGR, Abbott SBG. C1 neurons: the body’s EMTs. Am J Physiol Regul Integr Comp Physiol. 2013;305: R187-204. doi: 10.1152/ajpregu.00054.2013.
81. Osborn JW, Jacob F, Guzman P. A neural set point for the long-term control of arterial pressure: beyond the arterial baroreceptor reflex. Am J Physiol Regul Integr Comp Physiol. 2005;288: R846-55. doi: 10.1152/ajpregu.00474.2004.
82. Benarroch EE. Paraventricular nucleus, stress response, and cardiovascular disease. Clin Auton Res. 2005;15: 254-63. doi: 10.1007/s10286-005-0290-7.
83. Hendel MD, Collister JP. Contribution of the subfornical organ to angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2005;288: H680-5. doi: 10.1152/ajpheart.00823.2004.
84. Bains JS, Ferguson AV. Paraventricular nucleus neurons projecting to the spinal cord receive excitatory input from the subfornical organ. Am J Physiol. 1995;268: R625-33.
85. Braga VA, Medeiros IA, Ribeiro TP, França-Silva MS, Botelho-Ono MS, Guimarães DD. Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. Braz J Med Biol Res. 2011;44: 871-6. doi: 10.1590/S0100-879X2011007500088.
86. Kawano H, Masuko S. Region-specific projections from the subfornical organ to the paraventricular hypothalamic nucleus in the rat. Neuroscience. 2010;169: 1227-34. doi: 10.1016/j.neuroscience.2010.05.065.
87. Bains JS, Potyok A, Ferguson AV. Angiotensin II actions in paraventricular nucleus: functional evidence for neurotransmitter role in efferents originating in subfornical organ. Brain Res. 1992;599: 223-9.
88. Li Z, Ferguson AV. Subfornical organ efferents to paraventricular nucleus utilize angiotensin as a neurotransmitter. Am J Physiol. 1993;265: R302-9.
89. Biag J, Huang Y, Gou L, Hintiryan H, Askarinam A, Hahn JD, Toga AW, Dong H-W. Cytoand chemoarchitecture of the hypothalamic paraventricular nucleus in the C57BL/6J male mouse: a study of immunostaining and multiple fluorescent tract tracing. J Comp Neurol. 2011;520: 6-33. doi: 10.1002/cne.22698.
90. Wang G, Drake CT, Rozenblit M, Zhou P, Alves SE, Herrick SP, Hayashi S, Warrier S, Iadecola C, Milner TA. Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla. Brain Res. 2006;1094: 163-78. doi: 10.1016/j.brainres.2006.03.089.
91. Spary EJ, Maqbool A, Batten TFC. Changes in oestrogen receptor α expression in the nucleus of the solitary tract of the rat over the oestrous cycle and following ovariectomy. J Neuroendocrinol. 2010;22: 492-502. doi: 10.1111/j.1365-2826.2010.01977.x.
92. Xue B, Hay M. 17β-Estradiol inhibits excitatory amino acid-induced activity of neurons of the nucleus tractus solitarius. Brain Res. 2003;976: 41-52. doi: 10.1016/S0006-8993(03)02629-5.
93. Pierce JP, Kievits J, Graustein B, Speth RC, Iadecola C, Milner TA. Sex differences in the subcellular distribution of angiotensin type 1 receptors and NADPH oxidase subunits in the dendrites of C1 neurons in the rat rostral ventrolateral medulla. Neuroscience. 2009;163: 329-38. doi: 10.1016/j.neuroscience.2009.06.006.
94. Tanaka J, Miyakubo H, Okumura T, Sakamaki K, Hayashi Y. Estrogen decreases the responsiveness of subfornical organ neurons projecting to the hypothalamic paraventricular nucleus to angiotensin II in female rats. Neurosci Lett. 2001;307: 155-8.
95. Ciriello J, Roder S. 17β-Estradiol alters the response of subfornical organ neurons that project to supraoptic nucleus to plasma angiotensin II and hypernatremia. Brain Res. 2013;1526: 54-64. doi: 10.1016/j.brainres.2013.06.038.
96. Xue B, Zhao Y, Johnson AK, Hay M. Central estrogen inhibition of angiotensin II-induced hypertension in male mice and the role of reactive oxygen species. Am J Physiol Heart Circ Physiol. 2008;295: H1025-32. doi: 10.1152/ajpheart.00021.2008.
97. Gingerich S, Krukoff TL. Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptor β-dependent mechanism in hypothalamic slice cultures. Endocrinology. 2005;146: 2933-41. doi: 10.1210/en.2004-1375.
98. Milner TA, Thompson LI, Wang G, Kievits JA, Martin E, Zhou P, McEwen BS, Pfaff DW, Waters EM. Distribution of estrogen receptor beta containing cells in the brains of bacterial artificial chromosome transgenic mice. Brain Res. 2010;1351: 74-96. doi: 10.1016/j.brainres.2010.06.038.
99. Alves SE, Lopez V, McEwen BS, Weiland NG. Differential colocalization of estrogen receptor beta (ERbeta) with oxytocin and vasopressin in the paraventricular and supraoptic nuclei of the female rat brain: an immunocytochemical study. Proc Natl Acad Sci U S A. 1998;95: 3281-6.
100. Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S. Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol. 1998;36: 357-78. doi: 10.1002/(SICI)1097-4695(19980905)36: 3<357:: AID-NEU5>3.0.CO;2-V.
101. Wei S-G, Yu Y, Zhang Z-H, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009;296: H1425-33. doi: 10.1152/ajpheart.00942.2008.
102. Girouard H. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol. 2006;100: 328-35. doi: 10.1152/japplphysiol.00966.2005.
103. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension. 1988;12: 89-95. doi: 10.1161/01.HYP.12.2.89.
104. Iadecola C. Hypertension and dementia. Hypertension. 2014;64: 3-5. doi: 10.1161/HYPERTENSIONAHA.114.03040.
105. Calcinaghi N, Wyss MT, Jolivet R, Singh A, Keller AL, Winnik S, Fritschy J-M, Buck A, Matter CM, Weber B. Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. Stroke. 2013;44: 1957-64. doi: 10.1161/STROKEAHA.111.000185.
106. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol. 2011;300: H397-407. doi: 10.1152/ajpheart.00679.2010.
107. Duchemin S, Boily M, Sadekova N, Girouard H. The complex contribution of NOS interneurons in the physiology of cerebrovascular regulation. Front Neural Circuits. 2012;6: 51. doi: 10.3389/fncir.2012.00051.
108. Faraci FM. Effects of angiotensin II on the cerebral circulation: role of oxidative stress 1-11. 2012. doi: 10.3389/fphys.2012.00484/abstract.
109. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endotheliumdependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol. 2006;26: 826-32. doi: 10.1161/01.ATV.0000205849.22807.6e.
110. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95: 1019-26. doi: 10.1161/01.RES.0000148637.85595.c5.
111. Girouard H, Lessard A, Capone C, Milner TA, Iadecola C. The neurovascular dysfunction induced by angiotensin II in the mouse neocortex is sexually dimorphic. Am J Physiol Heart Circ Physiol. 2008;294: H156-63. doi: 10.1152/ajpheart.01137.2007.
112. Murata T, Dietrich HH, Xiang C, Dacey RG. G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/reoxygenation injury in male and female rats. Stroke. 2013;44: 779-85. doi: 10.1161/STROKEAHA.112.678177.
113. Reslan OM, Yin Z, do Nascimento GRA, Khalil RA. Subtype-specific estrogen receptormediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat. J Cardiovasc Pharmacol. 2013;62: 26-40. doi: 10.1097/FJC.0b013e31828bc88a.
114. Capone C, Anrather J, Milner TA, Iadecola C. Estrous cycle-dependent neurovascular dysfunction induced by angiotensin II in the mouse neocortex. Hypertension. 2009;54: 302-7. doi: 10.1161/HYPERTENSIONAHA.109.133249.
115. Li R, Singh M. Sex differences in cognitive impairment and Alzheimer’s disease. Front Neuroendocrinol. 2014;35: 385-403. doi: 10.1016/j.yfrne.2014.01.002.
116. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121: e46-215. doi: 10.1161/CIRCULATIONAHA.109.192667.
117. Roy-O’Reilly M, McCullough LD. Sex differences in stroke: The contribution of coagulation. Exp Neurol. 2014;259: 16-27. doi: 10.1016/j.expneurol.2014.02.011.
118. Milner E, Zhou M-L, Johnson AW, Vellimana AK, Greenberg JK, Holtzman DM, Han BH, Zipfel GJ. Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in tg2576 mice. Stroke. 2014;45: 3064-9. doi: 10.1161/STROKEAHA.114.006078.
119. Zhang X, Yeung PKK, McAlonan GM, Chung SSM, Chung SK. Transgenic mice overexpressing endothelial endothelin-1 show cognitive deficit with blood-brain barrier breakdown after transient ischemia with long-term reperfusion. Neurobiol Learn Mem. 2013;101: 46-54. doi: 10.1016/j.nlm.2013.01.002.
120. Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. J Alzheimers Dis. 2014. doi: 10.3233/JAD-141467.
121. Sayed K, Taha TTI, Saad M, Mohsen LA, Ibrahiem MA, Fadeel NAA, Sotouhy A. Is minimental score examination scoring a new predictor of uncontrolled hypertension? J Clin Hypertens. 2014;16: 348-53. doi: 10.1111/jch.12319.
122. Park L, Koizumi K, Jamal E, S, Zhou P, Previti ML, Van Nostrand WE, Carlson G, Iadecola C. Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy. Stroke. 2014;45: 1815-21. doi: 10.1161/STROKEAHA.114.005179.
123. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension. 2009;54: 1345-52. doi: 10.1161/HYPERTENSIONAHA.109.138586.
124. Strom JO, Theodorsson A, Theodorsson E. Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis. J Cereb Blood Flow Metab. 2009;29: 1359-72. doi: 10.1038/jcbfm.2009.66.
125. Davis CM, Fairbanks SL, Alkayed NJ. Mechanism of the sex difference in endothelial dysfunction after stroke. Transl Stroke Res. 2012;4: 381-9. doi: 10.1007/s12975-012-0227-0.
126. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev. 2008;60: 210-41. doi: 10.1124/pr.107.08002.
127. Fagernaes CF, Heuch I, Zwart JA, Winsvold BS, Linde M, Hagen K. Blood pressure as a risk factor for headache and migraine: a prospective population-based study. Eur J Neurol. 2014;22(1): 156-62. doi: 10.1111/ene.12547.
128. Martin VT. Migraine and the menopausal transition. Neurol Sci. 2014;35: 65-9. doi: 10.1007/s10072-014-1745-1.
129. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009;40: 2977-82. doi: 10.1161/STROKEAHA.109.547901.
130. Agostoni E, Aliprandi A. Migraine and hypertension. Neurol Sci. 2008;29: 37-9. doi: 10.1007/s10072-008-0883-8.
131. Ripa P, Ornello R, Pistoia F, Carolei A, Sacco S. The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev Neurother. 2014;14: 1043-55. doi: 10.1586/14737175.2014.946408.
132. Greenage M, Kulaksizoglu B, Cilingiroglu M, Ali R. The role of anxiety and emotional stress as a risk factor in treatment-resistant hypertension. Curr Atheroscler Rep. 2010. doi: 10.1007/s11883-010-0154-z.
133. Kovács KR, Szekeres CC, Bajkó Z, Csapó K, Molnár S, Oláh L, Magyar MT, Bereczki D, Kardos L, Soltész P, Bojtor AB, Csiba L. Cerebro-and cardiovascular reactivity and neuropsychological performance in hypertensive patients. J Neurol Sci. 2010;299: 120-5. doi: 10.1016/j.jns.2010.07.022.
134. Liu F, Havens J, Yu Q, Wang G, Davisson RL, Pickel VM, Iadecola C. The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress. Int J Physiol Pathophysiol Pharmacol. 2012;4: 28-35.
135. Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology. 2006;31: 1123-34. doi: 10.1038/sj.npp.1300921.
136. Lermer MA, Morra A, Moineddin R, Manson J, Blake J, Tierney MC. Somatic and affective anxiety symptoms and menopausal hot flashes. Menopause. 2011;18: 129-32. doi: 10.1097/gme.0b013e3181ec58f8.
137. Duchemin S, Belanger E, Wu R, Ferland G, Girouard H. Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol Behav. 2013;109: 63-8. doi: 10.1016/j.physbeh.2012.10.005.
138. Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The women’s health initiative trial and related studies: 10 years later: a clinician’s view. J Steroid Biochem Mol Biol. 2014;142: 4-11. doi: 10.1016/j.jsbmb.2013.10.009.
139. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol. 2008;51: 564-80. doi: 10.1097/GRF.0b013e318181de86.
140. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297: 1465-77. doi: 10.1001/jama.297.13.1465.
141. Modena MG, Sismondi P, Mueck AO, Kuttenn F, de Lignières B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR. New evidence regarding hormone replacement therapies is urgently required. Maturitas. 2005;52: 1-10. doi: 10.1016/j.maturitas.2005.05.003.
142. Cannoletta M, Cagnacci A. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. Int J Womens Health. 2014;6: 745-57. doi: 10.2147/IJWH. S61685.
143. White WB, Hanes V, Mallareddy M, Chauhan V. Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. J Am Soc Hypertens. 2008;2: 20-7. doi: 10.1016/j.jash.2007.08.004.
144. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation. 2001;103: 2903-8. doi: 10.1161/01.CIR.103.24.2903.
145. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011. doi: 10.1016/j.steroids.2011.03.001.
146. Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric. 2009;12 Suppl 1: 66-70.
147. LHermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013;16 Suppl 1: 44-53. doi: 10.3109/13697137.2013.808563.
148. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet. 2000;45: 327-30. doi: 10.1007/s100380070002.
149. Peter I, Shearman AM, Zucker DR, Schmid CH, Demissie S, Cupples LA, Larson MG, Vasan RS, D’Agostino RB, Karas RH, Mendelsohn ME, Housman DE, Levy D. Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens. 2005;23: 2193-200.
150. Hermida RC, Ayala DE, Mojon A, Fontao MJ, Chayan L, Fernandez JR. Differences between men and women in ambulatory blood pressure thresholds for diagnosis of hypertension based on cardiovascular outcomes. Chronobiol Int. 2013;30: 221-32. doi: 10.3109/07420528.2012.701487.
151. Marques-Lopes, J., Lynch, M.K. Van Kempen, T.A., Waters, E.M., Wang, G. Iadecola, C., Pickel*, V.M., and Milner*, T.A.: Female protection from slow-pressor effects of AngII involves prevention of ROS production independent of NMDA receptor trafficking in hypothalamic neurons expressing angiotensin-1A receptors. *Co-principal investigators. Synapse 69: 148-165 (2015).